Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues
作者:Judey Pretorius、Sarel F. Malan、Neal Castagnoli、Jacobus J. Bergh、Jacobus P. Petzer
DOI:10.1016/j.bmc.2008.07.088
日期:2008.9
The adenosine A(2A) receptor has emerged as an attractive target for the treatment of Parkinson's disease (PD). Evidence suggests that antagonists of the A(2A) receptor (A(2A) antagonists) may be neuroprotective and may help to alleviate the symptoms of PD. We have reported recently that several members of the (E)-8-styrylcaffeine class of A(2A) antagonists also are potent inhibitors of monoamine oxidase
腺苷A(2A)受体已成为治疗帕金森氏病(PD)的有吸引力的靶标。有证据表明,A(2A)受体拮抗剂(A(2A)拮抗剂)可能具有神经保护作用,并可能有助于减轻PD的症状。我们最近报道,(E)-8-苯乙烯基咖啡因类别的A(2A)拮抗剂的几个成员也是单胺氧化酶B(MAO-B)的有效抑制剂。由于已知MAO-B抑制剂具有抗帕金森氏症的特性,因此阻断MAO-B和A(2A)受体的双重靶标定向药物在PD的管理中可能具有更高的价值。为了进一步探索这个概念,我们准备了三类其他的C-8取代咖啡因类似物。选择时,8-苯基和8-苄基咖啡因基类似物显示出相对较弱的MAO-B抑制能力(E,发现E)-8-(4-苯基丁二烯-1-基)咖啡因基类似物是异常有效的可逆MAO-B抑制剂,其酶抑制剂解离常数(K(i)值)为17至149 nM。此外,这些(E,E)-8-(4-苯基丁二烯-1-基)咖啡因可作为有效的A(2A)拮抗剂,其K(i)值为59至153